Ocular Therapeutix, Inc. (OCUL) Covered Calls

Ocular Therapeutix, Inc. covered calls Ocular Therapeutix is a biopharmaceutical company developing innovative therapies for eye diseases. Using its proprietary bioresorbable hydrogel platform, the company creates sustained-release drug delivery solutions. Its portfolio includes treatments for post-surgical inflammation and allergic conjunctivitis, plus a pipeline for glaucoma and wet AMD.

You can sell covered calls on Ocular Therapeutix, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for OCUL (prices last updated Thu 4:16 PM ET):

Ocular Therapeutix, Inc. (OCUL) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
9.06 -0.10 8.90 9.36 2.6M - 2.0
Covered Calls For Ocular Therapeutix, Inc. (OCUL)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 9 0.70 8.66 3.9% 158%
Mar 20 9 3.60 5.76 56.2% 554%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Ocular Therapeutix, Inc. is a biopharmaceutical company dedicated to the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. The company leverages its proprietary ELUTYX technology platform, a bioresorbable hydrogel-based formulation, to provide sustained-release delivery of therapeutic agents, potentially replacing traditional eye-drop regimens with more consistent and convenient treatment options.

Core Business and Products

  1. DEXTENZA: The company's lead commercial product is an FDA-approved corticosteroid insert placed in the punctum to treat post-surgical ocular inflammation and pain, as well as ocular itching associated with allergic conjunctivitis.
  2. AXPAXLI: A clinical-stage intravitreal implant being developed for the treatment of wet age-related macular degeneration (wet AMD). It is designed to provide sustained release of axitinib over several months.
  3. PAXTRAVA: A sustained-release travoprost implant currently in clinical trials for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Competitive Landscape

The ophthalmic pharmaceutical market is highly competitive, characterized by rapid technological advancement. Ocular Therapeutix competes with large-scale pharmaceutical firms and specialized biotechnology companies. Key competitors include Regeneron Pharmaceuticals Inc and Bausch Health Companies, which offer established treatments for retinal diseases and inflammation. The company also faces competition from EyePoint Pharmaceuticals Inc and Aldeyra Therapeutics in the development of sustained-release delivery systems and novel ocular therapies. Other significant players in the space include Alcon and Novartis.

Strategic Outlook and Innovation

The company is focused on expanding its pipeline by applying its hydrogel technology to a broader range of front- and back-of-the-eye indications. A primary strategic priority is the advancement of the registrational clinical program for its wet AMD candidate, aiming to offer a differentiated treatment profile that reduces the frequency of intraocular injections. Additionally, the company is exploring the use of its platform for the treatment of diabetic retinopathy. By focusing on sustained-release technology, the company aims to improve patient compliance and clinical outcomes while reducing the overall treatment burden for chronic eye conditions.